Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:FOLD NASDAQ:UTHR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFOLDAmicus Therapeutics$14.49$14.42$5.51▼$14.50$4.55B0.482.62 million shs5.29 million shsUTHRUnited Therapeutics$528.47-0.2%$547.88$272.12▼$609.35$22.43B0.58404,784 shs307,226 shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFOLDAmicus Therapeutics0.00%0.00%0.00%0.00%+129.64%UTHRUnited Therapeutics0.00%-1.34%-2.75%-6.82%+72.92%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeFOLDAmicus Therapeutics$14.49$14.42$5.51▼$14.50$4.55B0.482.62 million shs5.29 million shsUTHRUnited Therapeutics$528.47-0.2%$547.88$272.12▼$609.35$22.43B0.58404,784 shs307,226 shs7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceFOLDAmicus Therapeutics0.00%0.00%0.00%0.00%+129.64%UTHRUnited Therapeutics0.00%-1.34%-2.75%-6.82%+72.92%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceFOLDAmicus Therapeutics 2.00Hold$14.560.50% UpsideUTHRUnited Therapeutics 2.85Moderate Buy$648.3322.68% UpsideCurrent Analyst Ratings BreakdownLatest UTHR and FOLD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/23/2026UTHRUnited Therapeutics JPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$685.00 ➝ $687.007/10/2026UTHRUnited Therapeutics Bank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$620.00 ➝ $613.007/7/2026UTHRUnited Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$701.00 ➝ $704.006/11/2026UTHRUnited Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy (B)5/21/2026UTHRUnited Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/7/2026UTHRUnited Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$516.005/7/2026UTHRUnited Therapeutics Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeEqual Weight ➝ Overweight$575.00 ➝ $735.005/7/2026UTHRUnited Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$707.00 ➝ $701.00(Data available from 7/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookFOLDAmicus Therapeutics$634.21M7.17$0.06 per share234.67$0.87 per share16.66UTHRUnited Therapeutics$3.18B7.05$32.99 per share16.02$164.81 per share3.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateFOLDAmicus Therapeutics-$27.11M-$0.08N/A18.82N/A-4.27%4.15%1.09%N/AUTHRUnited Therapeutics$1.33B$27.0919.5116.671.7740.62%19.24%17.25%8/5/2026 (Confirmed)Latest UTHR and FOLD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2026Q2 2026UTHRUnited Therapeutics$7.06N/AN/AN/A$804.65 millionN/A5/6/2026Q1 2026UTHRUnited Therapeutics$7.00$5.82-$1.18$5.82$797.40 million$781.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthFOLDAmicus TherapeuticsN/AN/AN/AN/AN/AUTHRUnited TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioFOLDAmicus Therapeutics1.432.841.88UTHRUnited TherapeuticsN/A4.794.50Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipFOLDAmicus TherapeuticsN/AUTHRUnited Therapeutics94.08%Insider OwnershipCompanyInsider OwnershipFOLDAmicus Therapeutics2.20%UTHRUnited Therapeutics8.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableFOLDAmicus Therapeutics480314.00 million307.09 millionOptionableUTHRUnited Therapeutics1,40042.45 million38.80 millionOptionableUTHR and FOLD HeadlinesRecent News About These CompaniesUnited Therapeutics Corporation $UTHR Shares Sold by Morningstar Investment Management LLCJuly 26 at 5:35 AM | marketbeat.comRenaissance Technologies LLC Has $1.06 Billion Stake in United Therapeutics Corporation $UTHRJuly 25 at 6:07 AM | marketbeat.comEpoch Investment Partners Inc. Cuts Stake in United Therapeutics Corporation $UTHRJuly 25 at 4:31 AM | marketbeat.comCritical Comparison: Ardelyx (NASDAQ:ARDX) versus United Therapeutics (NASDAQ:UTHR)July 25 at 2:45 AM | americanbankingnews.comJPMorgan Chase & Co. Forecasts Strong Price Appreciation for United Therapeutics (NASDAQ:UTHR) StockJuly 25 at 2:12 AM | americanbankingnews.comLiquidia vs. United Therapeutics: Which PAH Stock Is the Better Buy Now?July 24 at 12:00 PM | zacks.comUnited Therapeutics Corporation $UTHR Shares Sold by KBC Group NVJuly 24 at 5:05 AM | marketbeat.comBowen Hanes & Co. Inc. Makes New Investment in United Therapeutics Corporation $UTHRJuly 24 at 4:07 AM | marketbeat.comAtika Capital Management LLC Invests $7.32 Million in United Therapeutics Corporation $UTHRJuly 24 at 3:15 AM | marketbeat.comJPMorgan Chase & Co. Raises United Therapeutics (NASDAQ:UTHR) Price Target to $687.00July 23 at 3:11 PM | marketbeat.comUnited Therapeutics Adds Victor Dzau to BoardJuly 23 at 7:51 AM | tipranks.comUnited Therapeutics Corporation Announces Appointment of Victor Dzau to its Board of DirectorsJuly 23 at 6:30 AM | businesswire.comFirst Trust Advisors LP Has $160.45 Million Stock Position in United Therapeutics Corporation $UTHRJuly 23 at 4:00 AM | marketbeat.comUnited Therapeutics Corporation $UTHR Shares Sold by Dimensional Fund Advisors LPJuly 23 at 3:52 AM | marketbeat.comUnited Therapeutics (UTHR) Earnings Expected to Grow: What to Know Ahead of Q2 ReleaseJuly 22, 2026 | zacks.comUnited Therapeutics (UTHR) Projected to Release Quarterly Earnings on WednesdayJuly 22, 2026 | marketbeat.comSwiss National Bank Buys 2,320 Shares of United Therapeutics Corporation $UTHRJuly 22, 2026 | marketbeat.comMediolanum International Funds Ltd Decreases Position in United Therapeutics Corporation $UTHRJuly 22, 2026 | marketbeat.comAndra AP fonden Has $15.50 Million Stock Position in United Therapeutics Corporation $UTHRJuly 22, 2026 | marketbeat.com17,731 Shares in United Therapeutics Corporation $UTHR Purchased by SEB Asset Management ABJuly 21, 2026 | marketbeat.comCalifornia Public Employees Retirement System Grows Stock Holdings in United Therapeutics Corporation $UTHRJuly 21, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeUTHR and FOLD Company DescriptionsAmicus Therapeutics NASDAQ:FOLDAmicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.United Therapeutics NASDAQ:UTHR$528.47 -1.06 (-0.20%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$528.61 +0.14 (+0.03%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade? Broadcom May Be the Biggest Winner From Alphabet's Earnings CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
